Celldex Therapeutics Quarterly Balance Sheet
NASDAQ: CLDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Celldex Therapeutics financial position
As of Jun 30, 2026, Celldex Therapeutics reported total assets of $782.3 million, up 13.0% from a year earlier against total liabilities of $67.8 million. Shareholders' equity stood at $714.6 million, or 91.3% of assets. The company held $47.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 11.82, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Celldex Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 47.45M | 35.73M | 28.87M | 36.04M | 23.04M | 17.14M | 28.36M | 36.40M | 42.74M | 115.08M | 34.81M | 21.13M |
| Short-Term Investments | 670.13M | 415.73M | 489.70M | 547.19M | 607.29M | 656.15M | 696.92M | 719.60M | 759.58M | 708.77M | 388.78M | 214.21M |
| Total Current Assets | 724.93M | 459.22M | 534.66M | 604.34M | 648.40M | 693.76M | 747.16M | 778.84M | 811.98M | 835.32M | 431.69M | 245.93M |
| Property, Plant & Equipment | 9.76M | 7.40M | 5.33M | 4.83M | 4.39M | 4.60M | 4.35M | 4.23M | 3.86M | 4.06M | 4.06M | 4.16M |
| Intangible Assets | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M |
| Total Assets | 782.35M | 511.25M | 582.98M | 648.44M | 692.41M | 739.47M | 792.34M | 823.18M | 845.59M | 868.85M | 465.63M | 280.26M |
| Accounts Payable | 14.68M | 10.36M | 1.18M | 4.27M | 2.07M | 3.41M | 3.27M | 1.11M | 3.80M | 3.23M | 3.49M | 3.59M |
| Total Current Liabilities | 61.33M | 51.47M | 50.99M | 46.47M | 32.96M | 32.02M | 39.50M | 32.09M | 27.66M | 26.29M | 31.13M | 27.84M |
| Total Liabilities | 67.78M | 55.03M | 55.82M | 50.08M | 37.00M | 36.49M | 45.34M | 37.27M | 31.93M | 30.23M | 36.46M | 33.54M |
| Shareholders' Equity | 714.56M | 456.23M | 527.16M | 598.36M | 655.41M | 702.98M | 747.00M | 785.90M | 813.66M | 838.61M | 429.17M | 246.72M |
| Retained Earnings | -1.97B | -1.89B | -1.81B | -1.73B | -1.67B | -1.61B | -1.56B | -1.51B | -1.47B | -1.43B | -1.40B | -1.35B |
| Net Cash (Debt) | 717.59M | 451.46M | 518.57M | 583.22M | 630.34M | 673.29M | 725.28M | 756.00M | 802.32M | 823.85M | 423.60M | 235.35M |
| Shares Outstanding | 78.50M | 66.57M | 66.55M | 66.45M | 66.39M | 66.38M | 66.37M | 66.34M | 66.28M | 65.91M | 55.88M | 47.26M |
This table shows 12 quarterly periods of Celldex Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow CLDX's reporting calendar. What is a balance sheet?